Parallel Bio Secures $21 Million in Series A to Advance Human-First Drug Discovery
'Parallel Bio is redefining drug development by turning the conventional model upside down—transforming today's 95% failure rate into a pathway for 95% success."
Share
The company also revealed that 8 pharmaceutical partners, including three Fortune 500 companies, are testing more than 50 drugs and immunotherapies using its organoid-based immune system platform—including Centivax, which completed the first preclinical testing on the platform for its universal flu vaccine candidate.
'With these milestones, we are closer to making human-first drug discovery the new industry standard,' said Robert DiFazio, CEO and co-founder at Parallel Bio. 'For too long, the reliance on lab mice to model human biology has come at a high cost: 95% of drugs fail in human trials even after succeeding in animal studies. We're turning that on its head by using organoids and AI to discover drugs in true-to-life human models from the start.'
Parallel Bio will use the new capital to scale the AI and automation capabilities of its organoid-based immune system platform, expand its team of scientists and engineers, and support growing pharmaceutical partnerships. To date, Parallel Bio has raised a total of nearly $30 million, including this Series A and previous seed rounds.
Parallel Bio's platform combines lymph-node organoids with AI and robotics to replicate the human immune system at scale across diverse populations. Organoids are 3D, self-assembling models of human biology. These miniature organs mimic an organ's structure and function and the body's response to disease or treatment, as if the organoids were individual patients.
AIX Ventures partner Krish Ramadurai, who joined the company's board of directors as part of the round, commented: 'Parallel Bio is redefining drug development by turning the conventional model upside down—transforming today's 95% failure rate into a pathway for 95% success. Their groundbreaking human-first platform unlocks biological insights previously impossible to capture, accelerating the development of effective treatments that reach patients faster while generating de novo biological data to power the next generation of AI-driven therapeutics. We're thrilled to partner with the Parallel Bio team in setting a new gold standard for the future of medicine.'
Since launching Clinical Trial in a Dish last year, Parallel Bio has seen growing demand from pharmaceutical companies. This first commercial application accurately predicts the safest and most effective drug candidates for human trials.
'Starting with human models enables new drugs to reach the market at a pace never possible before,' said Juliana Hilliard, Parallel Bio co-founder and chief scientific officer. 'We aim to slash $2 billion and 9 years from each drug candidate in development by predicting success at the earliest stages of discovery.'
Centivax Validates Broad Immune Response in Organoid Trial
Parallel Bio partnered with Centivax, a universal immunity biotechnology company, to generate human-first data to validate Centivax's first program: a universal flu vaccine called Centi-Flu that is now in manufacturing for human clinical trials, with the first patient expected to be dosed early next year.
'Parallel Bio enables us to derisk the single biggest source of failure in vaccine development: making sure the vaccines work in humans before the human trials have even begun,' said Jacob Glanville, president and CEO at Centivax. 'Even though we have validated our pan-influenza responses in mice, rats, pigs, and ferrets, ultimately we are making a universal vaccine for humans. Parallel Bio's platform is transformative by allowing us to directly validate our results in immune organoids derived from adult humans.'
The organoid study revealed the power of the Centi-Flu technology: by effectively targeting common features of the virus shared by many different influenza strains, Centi-Flu even produces strong immune responses against strains not included in the vaccine. Human immune organoids were 'vaccinated' with Centi-Flu, leading to the production of B cells capable of reacting to a wide variety of flu strains. The immune organoids were derived from patients with prior flu exposure, proving that Centi-Flu could trigger broad humoral responses in flu-exposed individuals.
The organoid model also showed activation of CD4+ and CD8+ T cells, which are important for fighting infections, suggesting that Centi-Flu helps stimulate both antibody production and T cell immunity. This combination is particularly valuable for protecting against severe flu, including hospitalization and death.
About Parallel Bio
Parallel Bio is pioneering human-first drug discovery by combining organoids and AI to create true-to-life models of human biology. The company developed the first platform that replicates the human immune system across diverse populations, predicting drug success and identifying disease targets with accuracy and speed far beyond the limits of traditional animal models. Pharmaceutical partners, including three Fortune 500 companies, are using its Clinical Trial in a Dish to test the safety and efficacy of immunotherapies. Based in Cambridge, Mass., Parallel Bio was founded in 2021 by two scientists behind the world's first scalable human immune organoid.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
34 minutes ago
- Business Wire
Windancer Holdings Names Newest Partner, CFO Kyle Knezovich
DAYTON, Ohio--(BUSINESS WIRE)--Windancer Holdings, a Dayton-based investment firm, announced today the promotion of Kyle Knezovich to Partner. Knezovich, who joined the firm in May 2022, will continue to serve as Chief Financial Officer. Since joining Windancer, Knezovich has played a key role in building and scaling the firm's financial and operational infrastructure. As CFO, he spearheaded the firm's investment fund structure, working closely with legal and tax counsel, while leading initiatives across accounting, trading, transaction execution, and organizational policy. 'Being named Partner at Windancer Holdings is a meaningful milestone. It reflects the intense focus we've put into building the operational foundation and financial discipline that supports our investment success. That's what it means to live our principle to 'concentrate, it only takes one,'' Knezovich said. 'As CFO and now Partner, I remain focused on empowering our investment team through clear, decisive leadership. This promotion isn't just a title. It's a deeper commitment to Windancer's mission to be exceptional in every part of our process.' Shane Connor, Managing Partner, added: 'In three years, Kyle helped build and scale Windancer during a period when the firm doubled its headcount and grew assets under management by approximately $200 million. He takes ownership of everything he does. The decision to make him an owner of our firm was an easy one. Kyle lives Windancer's core value of 'Embrace the Pace' and sets the standard for the firm's financial and operational rigor.' Knezovich's promotion reflects Windancer's investment in leadership as the firm continues to scale with discipline and long-term focus. About Windancer Holdings Windancer Holdings, LLC is an investment firm focused on active, high-conviction investment with flexible, long-term committed capital. The firm invests in and partners with companies, funds, and people on an opportunistic and unconstrained basis. Its long-term approach and culture are driven by the experience and entrepreneurship of the Connor family and The Connor Group. For more information, please visit
Business Wire
34 minutes ago
- Business Wire
Summit Bank Announces the Addition of Max Williams to Its Portland Metro Advisory Board
PORTLAND, Ore.--(BUSINESS WIRE)--Summit Bank is pleased to announce the addition of Max Williams to its Portland Metro Advisory Board. Williams brings decades of cross-sector leadership experience and a long history of service to Oregon's public, private, and nonprofit sectors. Most recently, he served as President and CEO of the Oregon Community Foundation, where he led the organization through a decade of extraordinary growth and transformation, expanding total assets from $1.2 billion to $3.7 billion and more than doubling statewide grantmaking. Under his leadership, OCF became one of the top 10 community foundations in the country and a catalyst for innovation in philanthropy and equity. "Max brings a rare combination of strategic vision, legal expertise, and statewide leadership experience," said Brian Thomas, Senior Vice President and Commercial Team Lead for Summit Bank's Downtown Portland Office. Share Previously, Williams directed the Oregon Department of Corrections and served three terms in the Oregon Legislature, including as Chair of the House Judiciary Committee. His professional background also includes more than a decade practicing law with Miller Nash LLP. "Max brings a rare combination of strategic vision, legal expertise, and statewide leadership experience," said Brian Thomas, Senior Vice President and Commercial Team Lead for Summit Bank's Downtown Portland Office. "His insights will be incredibly valuable as we continue to grow our presence and impact in the Portland Metro region." Summit Bank's Advisory Boards are composed of respected leaders and professionals who provide insight into local economic needs and opportunities. Their guidance helps shape the Bank's mission of supporting Oregon's business community through personalized, relationship‑based banking. Williams continues to serve on numerous nonprofit boards and remains focused on strengthening the state's civic and economic infrastructure. He'll be joined on Summit Bank's Portland Advisory Board by the following esteemed Portland‑area leaders: Adam K. Abplanalp, Managing Principal and Director of Client Experience at Cobalt CPA Jessica Getman, President of Brown & Brown Northwest Insurance Jerry Elliott, President & Founder of EOP Law Orlando Williams, President, CEO, and Chief Equity Officer of Motus Recruiting & Staffing Vanessa Sturgeon, President & CEO of TMT Development Dr. Tom Beer, Deputy Director and Chief Medical Officer at OHSU Knight Cancer Institute Together, this board brings deep experience across accounting, insurance, commercial real estate, staffing, healthcare, and development—precisely the kind of strategic insight Summit Bank needs as an active partner to Portland's growing business community. ABOUT SUMMIT BANK: Summit Bank Group Inc., through its wholly-owned subsidiary Summit Bank, maintains offices in Eugene, Bend, Redmond, Downtown Portland, and Westside Portland, specializing in providing high-level service to professionals and medium-sized businesses and their owners. The Bank was voted one of Oregon's "Top 100 Companies to Work For" for the fourth consecutive year, according to Oregon Business Magazine. Summit Bank was honored as "Favorite Bank" in the Eugene Register-Guard's annual Reader's Choice Awards and "Best Bank" by Central Oregon's Bend Bulletin for the past two years. Recently, Summit Bank was recognized by American Banker as one of the top 100 banks in the country, affirming its position among the elite national financial institutions. Additionally, Lane County recently named Summit Bank one of the best places for parents to work. Summit Bank Group Inc. is quoted on the OTCPK under the symbol SBKO.
Business Wire
34 minutes ago
- Business Wire
BallotTrax™ Secures Second U.S. Patent for Mail Ballot Tracking and Voter Notification System
DENVER--(BUSINESS WIRE)--i3logix, the Denver-based software company behind BallotTrax ™, the country's first and only patented mail-ballot tracking and notification system, has been awarded a second new U.S. patent, solidifying its market position to deliver proactive ballot status alerts to voters. U.S. Patent No. 12,340,633, issued June 24, 2025, with a priority date of February 2, 2010, expands the company's IP protections. BallotTrax™ is now the only system with patented technology to notify voters—via text, email, or voice—of their ballot's status at each step of the mail voting process. 'Ballot status notifications have become one of the most cherished features of vote-by-mail systems,' said Steve Olsen, CEO of i3logix. 'Now that our technology is protected by patent, we're ensuring that counties and states can continue providing these critical alerts legally, reliably, and securely. Voter confidence depends on it.' The BallotTrax™ system receives data from ballot printers, election systems, and USPS scans. An intelligent barcode, linked to the voter's ID, is printed on outbound and inbound envelopes—never on the ballot itself—preserving privacy while enabling transparency. Voters choose how and when to receive alerts, with customizable delivery methods, languages, and notification windows. Counties use BallotTrax™ to automate outreach for issues such as signature mismatches or ballot rejections, and to offer helpful reminders and drop-off options. Vote-by-mail has surged in popularity since 2020, and BallotTrax™ now serves 19 states and nearly 400 counties—tracking approximately one in every four ballots cast in the United States. The company's first patent, issued in 2023, established a foundation for secure mail ballot tracking. The newly awarded patent expands those protections to cover additional aspects of the platform's architecture, alerting mechanisms, and voter customization features—ensuring that the BallotTrax™ intellectual property remains the only fully protected and compliant solution on the market. 'This patent underscores our leadership in secure, compliant, and voter-centric election technology,' Olsen added. 'We're committed to protecting the integrity of our system and ensuring that election officials have the most technologically advanced and protected system on the market.' Counties using BallotTrax™ report reduced administrative costs, improved vendor accountability, and significantly enhanced voter trust. i3logix continues to expand its IP portfolio and work closely with jurisdictions to ensure compliance ahead of upcoming elections. To explore how BallotTrax™ can support your next election, visit or contact Steve Olsen directly at solsen@ Founded in 2005, i3logix is a Denver-based information services and software development company specializing in secure, scalable solutions for elections, healthcare, and business intelligence. With a focus on innovation, transparency, and trust, i3logix empowers government and commercial clients to deliver efficient, user-friendly services that improve outcomes and customer experience. BallotTrax™, its flagship election product, is used by hundreds of jurisdictions nationwide to provide voters with real-time ballot tracking and notification.
